Page 124 - Demo
P. 124
en: https://www.fda.gov/drugs/drug-safetyand-availabilitysustained release hydrophilic matrix forrepaglinide. Int J Biol Macromol. 2017;97:721-32.39. Yang XD, Li WS, Tian YJ, Liu CG, Gao DH, Ma HL.Dissolution rate enhancement of repaglinide bysolid dispersion. Trop J Pharm Res. 8 de junio de2016;15(6):1123.40. Rautray RK, Biswal B, Patra RK, Mallik S. ResearchArticle Dissolution Rate Enhancement ofGanciclovir by Solid Dispersions withPolyethylene Glycol 6000. Res J Pharm Life SciVol. 2021;2(1):44-54.41. Ficha t%u00e9cnica Ixia 20 mg comprimidos recubiertoscon pel%u00edcula. [Internet]. Disponible en:https://cima.aemps.es/cima/dochtml/ft/65499/FT_65499.html42. Royce A, Ruegger C, Mecadon M, Karnachi A, ValazzaS. Scale-up of the compaction and tabletingprocess. En: Pharmaceutical Process Scale-Up.CRC Press; 2005. p. 405-42.43. Jain S, Patel K, Arora S, Reddy VA, Dora CP.Formulation, optimization, and in vitro%u2013in vivoevaluation of olmesartan medoxomilnanocrystals. Drug Deliv Transl Res.2017;7(2):292-303.44. Abd-El Bary A, D. Louis SS. Olmesartan medoxomilsurface solid dispersion- based orodispersibletablets: formulation and in vitrocharacterization. J Drug Deliv Sci Technol.2014;24(6):665-72.45. Chai R, Gao H, Ma Z, Guo M, Fu Q, Liu H, et al. InVitro and In Vivo Evaluation of OlmesartanMedoxomil Microcrystals and Nanocrystals:Preparation, Characterization, andPharmacokinetic Comparison in Beagle Dogs. CurrDrug Deliv. 2019;16(6):500-10.46. Listiohadi Y, Hourigan JA, Sleigh RW, Steele RJ.Thermal analysis of amorphous lactose and %u03b1lactose monohydrate. Dairy Sci Technol.2009;89(1):43-67.47. Aprilia NS, Davoudpour Y, Zulqarnain W, Khalil HA,Hazwan CCM, Hossain M, et al. Physicochemicalcharacterization of microcrystalline celluloseextracted from kenaf bast. BioResources.2016;11(2):3875-89.48. G%u00f3mez-Carracedo A, Alvarez-Lorenzo C, G%u00f3mezAmoza J, Concheiro A. Chemical structure andglass transition temperature of non-ioniccellulose ethers. J Therm Anal Calorim.2003;73(2):587-96.49. Nasr A, Gardouh A, Ghorab M. Novel Solid SelfNanoemulsifying Drug Delivery System(S-SNEDDS) for Oral Delivery of OlmesartanMedoxomil: Design, Formulation,Pharmacokinetic and Bioavailability Evaluation.Pharmaceutics. 2016;8(3):20.50. FDA updates and press announcements onangiotensin II receptor blocker (ARB) recalls(valsartan, losartan, and irbesartan): interimlimits for NDMA, NDEA, and NMBA in angiotensinII receptor blockers (ARBs). [Internet]. Disponible278ANALESRANFwww.analesranf.comGalenic development of a capsule containingrosuvastatin, repaglinide, and olmesartan minitablets for the treatment of metabolic syndromeRoc%u00edo Gonz%u00e1lez CrespoAn. R. Acad. Farm.Vol. 90. n%u00ba 2 (2024) %u00b7 pp. 257-278 Si desea citar nuestro art%u00edculo:Desarrollo gal%u00e9nico de una c%u00e1psula que contiene minicomprimidos de rosuvastatina, repaglinida y olmesartan para el tratamiento del s%u00edndrome metab%u00f3licoRoc%u00edo Gonz%u00e1lez CrespoAn Real Acad Farm (Internet).An.RealAcad.Farm.Vol.90.n%u00ba2(2024)%u00b7pp.257-278 DOI:http://dx.doi.org/10.53519/analesranf.2024.90.02.07
